Prof. Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Teharn University of Medical Sciences (TUMS), Iran

Prof. Ismaeil Haririan is a distinguished Professor of Pharmaceutics and Pharmaceutical Biomaterials at the Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), where he also serves as the Founder of the Department of Pharmaceutical Biomaterials and Head of the Biomaterials Research Center. He earned his Pharm.D. from Tabriz University and pursued a Ph.D. in Pharmaceutics at the University of London in 1993, followed by postdoctoral research in targeted drug delivery, which laid the foundation for his lifelong contributions to biomaterials and regenerative medicine. With over three decades of academic and research experience, Prof. Haririan has played a pioneering role in advancing interdisciplinary research that integrates pharmacy, materials science, and biomedical engineering. His research interests span the design of hyaluronic acid hydrogels for bone and cartilage regeneration, 3D pharming and bioprinting, microfluidics in pharmaceutical applications, drug delivery systems, nanomedicine, and pharmaceutical rheology. He has authored more than 120 SCI-indexed articles, earning over 3,600 citations, an h-index of 34, and an i10-index of 65, reflecting the global impact of his work. His research skills extend across tissue engineering, drug delivery system design, nanostructure characterization, and translational medicine, complemented by his strong expertise in mentoring doctoral candidates and industrial trainees. Recognized internationally as a leading figure in pharmaceutical biomaterials, Prof. Haririan has received numerous awards and honors, including recognition as a world leader in bioprinting research between 2022 and 2025. Beyond his scholarly contributions, he has served in editorial capacities, led major research collaborations, and advanced education by supervising Pharm.D. and Ph.D. students. In conclusion, Prof. Haririan embodies academic excellence, visionary leadership, and innovative research, making him one of the most influential scientists in pharmaceutics and biomaterials whose work continues to inspire progress in regenerative medicine and pharmaceutical sciences worldwide.

Featured Publications

Al-Jawadri, A. M. H., Karami, Z., Haririan, I., Akrami, M., & Gholami, M. (2025). Development of a bio-inspired phagocytic stable nanoghost with anti-inflammatory properties for management of inflammation in ulcerative colitis. Journal of Drug Targeting, 33(7), 1-15.

Safari, F., Goudarzi, A., Abolghasemi, H., Mohammad, H. A., Akrami, M., Mohammadi, S., & Haririan, I. (2025). Additive manufacturing of regorafenib tablets: Formulation strategies and characterization for colorectal cancer. Polymers, 17(17), 2302.

Sohrabi, R., Miri, A. H., Rad-Malekshahi, M., Saadatpour, F., Pourjabbar, B., Keshel, S. H., Arefian, E., Balalaei, S., Masoumi, A., Khalili, F., Haririan, I., Akrami, M., & Shahriari, M. H. (2025). Corrigendum to “Development of silk fibroin/collagen film containing GI-20 peptide-loaded PLGA nanoparticles against corneal herpes simplex virus-1” [International Journal of Pharmaceutics, 669 (2025), 125022]. International Journal of Pharmaceutics, 674, 125369.

Torabi, M., Haririan, I., Foroumadi, A., Ghanbari, H., & Ghasemi, F. (2024). A deep learning model based on the BERT pre-trained model to predict the antiproliferative activity of anti-cancer chemical compounds. SAR and QSAR in Environmental Research, 35(11), 971-992

Assoc. Prof. Dr. Kui Chen | Biomaterials | Best Researcher Award

Associate researcher, Institute of High Energy Physics Chinese Academy of Sciences, China.

Kui Chen is an emerging scientist with a background in bioinorganic chemistry, focusing on cutting-edge research in controlled-release nanosystems, particularly for Boron Neutron Capture Therapy (BNCT). After obtaining his PhD from the Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, he was promoted to Associate Professor in 2022. He has published 20 SCI papers in prestigious journals and holds over 20 patent applications, with 7 granted. His selection for the Beijing Nova Program further highlights his exceptional research capabilities and potential.

Publication profile

Scopus Profile

Education and Experience

Kui Chen completed his doctoral studies in bioinorganic chemistry at the Institute of High Energy Physics (IHEP), Chinese Academy of Sciences. His research was guided by Prof. Gengmei Xing and Academician Zhao Yuliang, both of whom are leaders in the field of nanotechnology and material science. During his PhD, Chen focused on applying bioinorganic principles to design and develop innovative drug delivery systems. His academic training provided a strong foundation in both materials science and chemistry, which he integrated into his research on controlled-release nanosystems. This interdisciplinary approach to education has played a significant role in shaping Chen’s scientific career. His education has been further strengthened by collaborative projects and cross-team initiatives, such as the Beijing Nova Program, which have expanded his expertise and allowed him to contribute to cutting-edge advancements in cancer therapy.

Work Experience

Kui Chen has been actively involved in research and academia since completing his PhD. After joining the Institute of High Energy Physics (IHEP) as a researcher, he quickly gained recognition for his contributions, leading to his promotion to Associate Professor in 2022. Chen has experience leading projects focused on developing novel nanosystems for medical applications, particularly in the treatment of cancer. His role as a corresponding and first author on 20 SCI papers demonstrates his leadership in scientific publications. In addition, Chen has filed over 20 patents, with 7 already granted, showcasing his ability to translate research into innovative, patentable technologies. His experience also includes collaboration with interdisciplinary teams, particularly through the Beijing Nova Program, where he plays a key role in cross-team projects aimed at advancing nanomedicine and drug delivery.

Awards and Honors

Kui Chen has been recognized for his groundbreaking research with numerous honors and awards. Among his most notable achievements is his selection for the prestigious Beijing Nova Program, an initiative that supports young scientists who demonstrate exceptional promise in their fields. In addition, Chen has been selected for the Cross-Team within the Beijing Nova Program, further highlighting his collaborative abilities and leadership in scientific research. His innovation and contributions to nanomedicine and drug delivery have earned him recognition in both national and international scientific communities. Chen’s work, which bridges bioinorganic chemistry and materials science, has also led to the granting of 7 patents, reflecting his commitment to translating research into practical solutions. These accomplishments underscore his growing influence in the field of medical nanotechnology and highlight his potential as a future leader in scientific research.

Research Focus

Kui Chen’s research is focused on developing advanced drug delivery systems, with a particular emphasis on Boron Neutron Capture Therapy (BNCT) for cancer treatment. His work integrates principles from bioinorganic chemistry and nanotechnology to design controlled-release nanosystems, such as exosomes and microparticles, for the precise delivery of boron-based drugs. These systems aim to enhance the efficacy of BNCT by improving the targeting and release mechanisms of therapeutic agents. Chen’s research also extends to developing nanosystems for radiocatalytic sensitizers, which are designed to improve the local environment of tumors, making them more responsive to radiotherapy. His interdisciplinary approach combines materials science, chemistry, and biomedical engineering, and his work has been published in top-tier journals, demonstrating its impact and relevance. Chen’s research is poised to significantly advance cancer therapies by offering more effective and targeted treatment options.

Conclusion

Kui Chen is a highly suitable candidate for the Best Researcher Award. His outstanding research contributions, strong publication record, innovative patents, and selection for competitive programs demonstrate his potential and impact in his field. Although his focus is specialized, expanding his interdisciplinary work and mentorship roles can further solidify his standing as a leader in both the scientific and academic communities. His dedication to pushing the frontiers of nanotechnology in medical treatments positions him as a future leader in materials science research.

Publications

Enhanced osteogenic differentiation for osteoporosis treatment through controlled icariin release in the bone cavity via extracorporeal shock wave
Authors: Li, H., Hu, F., Liu, Q., Xing, G., Chen, K.
Year: 2024
Citations: 0

Boron Neutron Capture Therapy-Derived Extracellular Vesicles via DNA Accumulation Boost Antitumor Dendritic Cell Vaccine Efficacy
Authors: Lv, L., Zhang, J., Wang, Y., Xing, G., Chen, K.
Year: 2024
Citations: 0

Boron-Containing MOF Nanoparticles with Stable Metabolism in U87-MG Cells Combining Microdosimetry To Evaluate Relative Biological Effectiveness of Boron Neutron Capture Therapy
Authors: Wang, Z., Lei, R., Zhang, Z., Li, J., Xing, G.
Year: 2024
Citations: 3

Boron-Containing Mesoporous Silica Nanoparticles with Effective Delivery and Targeting of Liver Cancer Cells for Boron Neutron Capture Therapy
Authors: Tang, H., Wang, Z., Hao, H., Li, J., Xing, G.
Year: 2024
Citations: 0

Application and Development of Tumor-Targeting Boron Carriers in Boron Neutron Capture Therapy
Authors: Chen, K., Lyu, L.-W., Xing, G.-M.
Year: 2023
Citations: 0

Well-established immunotherapy with R837-loaded boron neutron capture-shocked tumor cells
Authors: Chen, K., Liu, S., Lv, L., Liang, T., Xing, G.
Year: 2023
Citations: 7

A Bone-Penetrating Precise Controllable Drug Release System Enables Localized Treatment of Osteoporotic Fracture Prevention via Modulating Osteoblast-Osteoclast Communication
Authors: Liang, H., Chen, K., Xie, J., Xing, G.
Year: 2023
Citations: 7

Corrigendum to: “Reversing the pathological microenvironment by radiocatalytic sensitizer for local orthotopic osteosarcoma radiotherapy enhancement”
Authors: Chen, K., Zhou, R., Liang, H., Xing, G., Gu, Z.
Year: 2023
Citations: 0

3D culture boosting fullerenol nanoparticles to induce calreticulin exposure on MCF-7 cells for enhanced macrophage-mediated cell removal
Authors: Liu, S., Liang, H., Lv, L., Chen, K., Xing, G.
Year: 2023
Citations: 2

High-Throughput and Efficient Intracellular Delivery Method via a Vibration-Assisted Nanoneedle/Microfluidic Composite System
Authors: Li, X., Ma, Y., Xue, Y., Han, X., Wang, J.
Year: 2023
Citations: 10

Tag: Outstanding Biomaterials Researcher Award

Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award